Guidance
Evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Get involved
We want you to be involved in our work. There are many ways you can get involved as a healthcare professional or a member of the public.
Tell us what matters to you, your organisation or your community and we’ll share our latest news, features and guidance.
About us
Find out more about
and how we support
The NICE strategy 2021 to 2026 sets out an ambitious vision for our future.
Latest news
-
An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.
-
Around 4,000 people are set to benefit from a step-change in treatment for early breast cancer following today’s (17 June 2022) provisional approval by NICE of abemaciclib in combination with hormone therapy as an option after surgery.
-
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance today (16 June 2022).
-
NICE has today (10 June 2022) published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of a type of blood fat called triglycerides.
Explore NICE
Into practice
Resources to help you use our guidance and quality standards
Financial planning
Advice and tools to help you make the best use of your resources
Antimicrobial resistance
View our antimicrobial prescribing guidelines
Our role in patient safety
Our guidelines make evidence-based, best practice recommendations.
Find journals and databases
Access to a range of journals and other evidence-based resources.